MAJOR BIOACTIVE PROPERTIES OF GANODERMA POLYSACCHARIDES: A REVIEW by AHMAD BHAT, ZAHOOR et al.
Vol 14, Issue 3, 2021
Online - 2455-3891 
Print - 0974-2441
MAJOR BIOACTIVE PROPERTIES OF GANODERMA POLYSACCHARIDES: A REVIEW
ZAHOOR AHMAD BHAT*, ABDUL HAMID WANI, JOHN MOHD WAR, MOHD YAQUB BHAT
Department of Botany, Section of Plant Pathology and Mycology, University of Kashmir, Hazaratbal, Srinagar, India.  
Email: zahoorbht20@gmail.com
Received: 27 November 2020, Revised and Accepted: 31 December 2020
ABSTRACT
Ganoderma a white rot fungus has been used as a folk remedy for promoting health and longevity for centuries. The vast amount of study has been 
performed on the medicinal properties of Ganoderma in general and Ganoderma lucidum in particular. The bioactivities of the metabolites reported 
from G. lucidum are immense. The main bioactive metabolites of G. lucidum consist of mainly polysaccharides and triterpenoids. The major bioactive 
polysaccharides isolated from Ganoderma species are β (1→3), β (1→4), and β (1→6)-D glucans. With respect to the pure chemical and structural 
points of view, G. lucidum polysaccharides are mostly composed of β-glucans, heteropolysaccharides, and glycoptoteins. The major component of this 
sugar molecule is glucose together with xylose, mannose, galactose, and fructose in different conformations. Many of these bioactive polysaccharides 
have shown activities against the major diseases of our time and the list of effects shown is huge. Various important bioactivities, namely, antitumor, 
antioxidant, cytotoxic, immunomodulatory, antibacterial, anti-inflammation, neuroprotective, hepatoprotective, anti-HIV, and so on have been shown 
by these bioactive polysaccharides. The main purpose of this review is to report the most bioactive polysaccharides from G. lucidum and other species 
of Ganoderma and to report their potential health benefits.
Keywords: Ganoderma lucidum, β-glucans, Bioactive metabolites, Antitumor, Antioxidant.
INTRODUCTION
The mushroom is a macrofungus with a distinctive fruiting body that 
can be either epigeous (aboveground) or hypogeous (underground) and 
large enough to be seen with the naked eye and to be picked by hand [1]. 
Mostly mushrooms belong to class Ascomycetes and Basidiomycetes 
of the fungal kingdom. It is estimated that out of 1.5 million species 
of fungi existing on this biosphere 140,000 species are considered as 
mushrooms [2]. Only 14,000 species are known to man, which would 
account for 10% of the estimated mushroom species [3]. About 7000 
species are considered to possess varying degree of edibility and 
more than 3000 species from 31 genera are regarded as prime edible 
mushrooms. About 2000 medicinal mushrooms are known with a 
variety of health attributes [4]. These mushrooms possess enormous 
metabolites with nutraceutical and therapeutic significance [5].
Ganoderma belongs to wood rotting mushroom having hard fruiting 
body which grows on decaying logs of wood. Taxonomic studies have 
reported about 300 species in the genus Ganoderma and majority of 
which are mostly distributed in tropical regions [6,7]. The fruiting 
bodies of Ganoderma species are thick, corky, and tough and do not 
have the fleshy texture and are therefore not listed among edible 
mushrooms [8,9]. Some of the important species of Ganoderma 
on which most of the research work on medicinal aspects have 
been carried out are: Ganoderma lucidum, Ganoderma applanatum, 
Ganoderma pfeifferi, Ganoderma sinensis, Ganoderma theaecolum, 
Ganoderma colossum, Ganoderma zonatum, Ganoderma australe, 
Ganoderma tsugae, Ganoderma amboinense, Ganoderma resinaceum, 
Ganoderma formosanum, and Ganoderma atrum. G. lucidum is the 
most commonly characterized medicinal mushroom of the genus 
Ganoderma [10-15]. It is commonly known as “Reishi” in Japan, 
“Lingzhi” in China, and “Yeongji” in Korea. The highly ranked G. lucidum 
in oriental traditional medicine has been used as a remedy for number 
of chronic diseases such as hypertension, insomnia, asthma, arthritis, 
diabetes, hepatopathy, nephritis, bronchitis, and cancer [16-19]. 
For the promotion of longevity and the maintenance of vitality, the 
crude extract of G. lucidum has been used in Traditional Chinese 
Medicine [20,21]. G. lucidum was considered as an “elixir that could 
revive the dead” [10,22]. Mizuno et al., 1995 [23], have reported the 
composition of G. lucidum extract (% of dry weight), which consisted 
of Folin-positive material (68.9%), glucose (11.1%), protein (7.3%), 
and metals (10.2%) (K, Mg, and Ca are the major components with 
Ge having the 5th highest metal concentration at 489 mg/g). However, 
there are qualitative and quantitative differences in the chemical 
composition of G. lucidum products depending on the strain, origin, 
extracting process, and cultivation conditions.
As per traditional Chinese medicine, G. lucidum supports numerous 
health benefits and studies through animal models and molecular based 
research techniques have demonstrated vast array of pharmacological 
effects [8,13,24]. G. lucidum, more specifically has shown tremendous 
potential in the treatment of modern deadly diseases such as 
antitumor [25,26], antioxidant [27], immunoregulation [28], 
hepatoprotection [29], hypoglycemic effect [30,31], antibacterial 
activity [32], reduction of blood cholesterol [33,34], inhibition of 
angiogenesis [35,36], antifibrotic activity [37], anti-HIV activity [38], 
and reduction of lower urinary tract symptoms [39]. These bioactivities 
of Ganoderma have been considered due to the main bioactive 
compounds: Terpenoids and polysaccharides. In addition, other 
bioactive metabolites such as lectins, proteins, adenosine, peptides, 
and sterols have also been found to play an important role in these 
functions [40-46]. The mechanisms of action of different active 
components of G. lucidum and other Ganoderma species have remained 
poorly defined, despite the numerous reported medicinal properties 
of G. lucidum. Due to the advancement in modern research techniques, 
detailed insights into these mechanisms of action in which G. lucidum 
can influence the observed health benefits are becoming increasingly 
possible. Understanding the mechanisms of action may lead to more 
vigorous use of Ganoderma as an anti-carcinogenic agent. Due to 
the improvement in techniques, better separation and purification 
techniques have proved beneficial for the isolation and identification 
of some of the active components in G. lucidum. However, modern 
researchers have primarily focused more on two active components, 
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namely, triterpenes and polysaccharides. In this review, emphasis has 
been given on the work carried on bioactive polysaccharides found in 
G. lucidum and other species of Ganoderma.
POLYSACCHARIDES
Polysaccharide is a polymer of long chain sugar molecules which are 
joined together by glycosidic bonds. Several studies have revealed that 
mushrooms possess biologically active polysaccharides with several 
medicinal benefits [23,28,47-53]. In this review; however, emphasis 
will be given on the studies carried out on the medicinal properties 
of various biologically active polysaccharide molecules from species 
of Ganoderma (Table 1). Vast array of polysaccharides with molecular 
weights ranging from 4 × 105 to 1 × 106 Da has been identified from G. 
lucidum [13]. Sanodiya et al., 2009 [13], also reported that irrespective 
of the molecular weights of the identified polysaccharides, number 
of them have positive impacts on reducing cancer progression. About 
200 polysaccharides have been reported from G. lucidum. The major 
bioactive polysaccharides isolated from Ganoderma species are β 
(1→3), β (1→4), and β (1→6)-D-glucans. Structural analysis of the 
identified polysaccharides has shown that these polysaccharides are all 
heteropolysaccharides [54]. The major component of this sugar molecule 
is glucose together with xylose, mannose, galactose, and fructose 
in different conformations. It is believed that the polysaccharides 
extracted and identified from different parts of G. lucidum can induce 
different immune responses with varying degree of immune potential 
activities [54]. According to recent studies by Chow-Chin et al., 
2008 [55], β-D-glucan of polysaccharide from G. lucidum was found to 
be carcinostatic substance. G. lucidum contains glycans as a large group 
of polysaccharide. Glycans consists of mannose, fucose, arabinose, 
glucuronic acid, xylose, glucose, and galactose [56]. In addition, the 
other pharmacological properties of polysaccharides were reported 
such as neuroprotective effect [57], hepatoprotective [58], anticancer 
effect [59,60], anti-amnesic effect [61], anti-epileptic effect [62], anti-
obesity effect [63], antimicrobial [64-66], antidiabetic [67], and anti-
depressant [68]. Recently Li et al., 2018 [69], carried an extensive 
work on comparison of polysaccharides from G. lucidum and G. sinense 
and these two species showed antitumor, immunomodulatory, and 
gut microbiota modulatory activities. The polysaccharides from these 
two mushroom species have been compared systematically through 
a series of biological and chemical experiments. This study revealed 
that the polysaccharides from these two mushroom species shared 
the same structural features with respect to mono-/oligo-saccharide 
composition, molecular weight, sugar linkages, and NMR/IR spectra. 
The polysaccharides from these two species showed similar tumor-
suppressive property in mice (4T1 breast cancer in BALB/C mice). 
The study on RAW264.7 cells showed that these polysaccharides 
exhibit similar inducing effects to macrophages, as evaluated in 
the phagocytosis function, nitric oxide (NO)/cytokines production, 
inhibition against the viability and migration of cancer cells. Mechanistic 
investigation revealed the identical activation through toll-like receptor 
(TLR)-4 related MAPK/NF-κB signaling pathway and gut-microbiota 
modulatory effects.
The solubility characteristics and different branching conformation 
affect the anti-tumorigenic properties of these polysaccharides 
[70]. Polysaccharides having structure β-D-glucans consisting of 
(1→3), (1→4), and (1→6)-β-D linkages are known to have robust 
antitumor potential and better absorption than other polysaccharides 
identified from G. lucidum [70]. The polysaccharides from Ganoderma 
which is the prominent component of water extracts have been 
studied and investigated very recently. The branched polysaccharide 
arabinoxyloglucan from G. lucidum was first isolated by Miyazaki and 
Nishijima in 1981 [71] and it was demonstrated to possess antitumor 
activity. Since after this study, various kinds of biologically active 
polysaccharides have been isolated and studied from different species 
of Ganoderma [72-79]. Further, the spores and mycelium of Ganoderma 
can also produce various polysaccharides with significant biological 
activities [80,81]. Research on bioactive polysaccharides has shown 
a considerable progress with the development of advanced molecular 
biology tools, therefore the scope of prebiotics and other related benefits 
research has now shifted from basic to applied science [82-84]. The 
research which has been carried out revealed that numerous mushrooms 
possess different biologically active polysaccharides with prebiotic, 
antimicrobial, anti-oxidant, and immunomodulating properties. 
With respect to the pure chemical and structural points of view, 
G. lucidum polysaccharides are mostly composed of β-glucans, 
heteropolysaccharides, and glycoptoteins [85-87]
CHEMICAL FEATURES OF THE MOST COMMON GANODERMA 
POLYSACCHARIDES
Various biologically active polysaccharides from the fruiting bodies 
of G. lucidum have been isolated and these are considered as one of 
the main and robust bioactive metabolites present in the Ganoderma 
genus. Various researchers have reported on the islolation, structural 
elucidiation, and bioactivities of Ganoderma polysaccharides. The results 
from these researches have indicated about structural characterization 
that α or β (1→3), (1→6)-glucans, and other heteropolysaccharides 
conjugated to galactose, glucose, mannose, arabinose, xylose, and 
fucose were the most predominant. Various polysaccharides have 
been isolated and structurally characterized from G. lucidum; however, 
various new polysaccharides from G. lucidum are being revealed by 
modern analytical chemistry [88]. The major polysaccharides which 
have been isolated and structurally characterized from the G. lucidum 
showed to have a backbone of β-(1→3)-linked-D-glucopyranosyl 
residues, with branches of mono, di, and oligosaccharide side chains 
substituting at the C-6 of the glucosyl residues in the main chain. The 
studies which have been investigated on these polysaccharides have 
suggested an important finding that the degree of substitution of the 
backbone chain and the length of the branching chain might be having 
some important role in determining the bioactivities of β-(1-3)-linked 
glucans [75,89]. The polysaccharides isolated from Ganoderma by 
different researchers are composed of glucose, galactose, mannose, 
arabinose, xylose, and fucose, having different types of combinations 
and glycosidic linkages and which can bind to peptide or protein 
residues (polysaccharide-protein or peptide complexes) [46,70,90-93]. 
These polysaccharides are characterized by their molecular weight, 
degree of branching, and higher tertiary structures [46] and these 
polysaccharides are having different compositions, constituted by 
β-glucans, hetero-β-glucans, and heteroglycans or α-manno-β-glucan 
complexes [94]. Ganoderma polysaccharides such as homo-glucans are 
linear or branched biopolymers which possess backbone consisting of α 
or β-linked glucose units (1→3), (1→6)-β-glucans, and (1→3)-α-glucans 
and may possess side-chains attached at different positions. Out of the 
all homo-glucans, β-glucans are glucose polymers that exist as non-
branched (1→3)-β-linked backbone or as (1→3)-β-linked backbone 
with (1→6)-β-branches [46,94]. These polysaccharides of Ganoderma 
contain either linear or branched molecules with backbone composed 
of α or β-linked glucose units, with side chains that are attached in 
various ways. The Hetero-glucan side chains contain glucuronic acid, 
galactose, xylose, mannose, arabinose or ribose moieties as main 
component or in different combinations [28,46].
The other polysaccharides found in Ganoderma are Glycans. In 
general, these glycans contain units other than glucose in their 
backbone which are classified as galactans, xylans, mannans, and 
fucans by the individual sugar components in the backbone [94]. The 
Hetero-glycan side chains possess glucuronic acid, glucose, xylose, 
galactose, mannose, arabinose, and fucose as the main component or 
in various other combinations [28,94]. Ganoderma polysaccharides 
are also covalently bound to peptides or proteins as polysaccharide-
protein or peptide complexes, which show antitumor and antioxidant 
activities [46,95]. G. lucidum immunomodulating substance (GLIS) 
example of proteoglycan is a bioactive proteoglycan isolated from 
G. lucidum fruiting bodies. GLIS possesses carbohydrate and protein in 
the ration of 11.5:1, the carbohydrate portion being formed by seven 
different monosaccharide’s, predominantly D-glucose, D-galactose, and 
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Mushroom Source Bioactive Polysaccharide 






















against Sarcoma 180 
solid tumor
[71]








a cascade of 
immunomodulatory 
cytokines against 
Sarcoma 180 solid 
tumor
[106]
G. tsugae Mycelium 
(cultivated)
Hetero-glucans (GTM3; 










Immersion in 0.2 M 
sodium phosphate 
buffer (pH 7.0); Sevag 
method; H2O2; dialysis; 
isolation with phosphate 
buffer, distilled water 
and 0.5 NaOH
Antitumor activity 
against Sarcoma 180 
solid tumor
[80]
G. lucidum Fruiting body 
(cultivated)
Heteropolysaccharide
de (GP1 and GP2)














breast cancer cell 
line (MDA-MB-231)
[100]

















cell line (HepG2) 
and tumor 
xenografts in ICR 
mice
[99,108]
G. lucidum Fruiting body 
(cultivated)
Heteroglycans
GLP, GLP1, GLP2, GLP3, 
GLP4)










gland from rat-PC12 
cell line
[109]












First extraction with 
cold PBS (separation of 
soluble and insoluble 
fractions). Hot water, 
cold and hot 1M NaOH; 
treatment with cetyl 
pyridinium chloride 
and glucoamylase; acid 
hydrolysis
Antitumor activity 
against Sarcoma 180 
solid tumor
[70]








against Sarcoma 180 
solid tumor
[70]
G. lucidum Fruiting body
(cultivated)









G. lucidum Fruiting body 
(Wild)
Na Na Hot water Antimicrobial 
activity in vitro 
by agar diffusion 
method
[139]
G. applanatum Fruiting body 
(Wild)
Na Na Na Antimirobial activity 
in vitro by cup 
diffusion method
[136]











followed by fractionation 





Table 1: Polysaccharides from Ganoderma and their bioactivity
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Table 1: (Continued)
Mushroom Source Bioactive Polysaccharide 
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[182]
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Homopolysaccharide
Main glycosidic bond (na)
Mannose Hot water extraction; 
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DEAE –sepharose fast 
flow
Antioxidant activity 
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Table 1: (Continued)
Mushroom Source Bioactive Polysaccharide 
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assisted extraction; 
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Unreported [176]
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Mushroom Source Bioactive Polysaccharide 
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Extracted by water, 95% 
ethanol, centrifugation, 
vacuum concentrator, 
filtration by Spectrum 
KrosFlo system
Anti-obesity [63]
Na: Data not available, G. lucidum: Ganoderma lucidum, G. tsugae: Ganoderma tsugae, G. applanatum: Ganoderma applanatum, G. formosanum: Ganoderma formosanum, 
G. japonicum: Ganoderma japonicum, G. resinaceum: Ganoderma resinaceum
Table 1: (Continued)
D-mannose in the molar ratio of 3:1:1 [96]. Therefore, polysaccharides 
from Ganoderma have been under special consideration and attention 
as they have robust capability for carrying biological information, 
because they show great potential for structural variability [28].
Ganoderma has been most widely used in medicine and functional foods 
to promote health. The polysaccharides identified from Ganoderma 
have attracted considerable attention of scientists due to the potentially 
significant bioactivities such as antitumor, immunomodulatory, 
antioxidant, antimicrobial, antihypertensive, and hepatoprotective 
activities (Table 1). The bioactivities of Ganoderma polysaccharides as 
reported by several workers are summarized below:
ANTITUMOR ACTIVITIES
The traditional Chinese medicine has used the crude water soluble 
extracts of Ganoderma species as immunomodulating and antitumor 
agents [97]. The antitumor activity of polysaccharides of Ganoderma 
has been found to be mainly related to the host-mediated immune 
function [11,20,98,99]. Liew et al., 1992 [20], observed the effect of 
G. lucidum on induction of differentiation in Leukemic U937-cells. 
The polysaccharides from the Ganoderma in general and G. lucidum in 
particular have received special attention from the scientific world and 
the polysaccharides from Ganoderma have been demonstrated to have 
robust antitumor activity both under in vivo and in vitro conditions [25]. 
Polysaccharides from G. lucidum with bioactivity have been isolated 
from the fruiting body [75,100] and also from the mycelium cultivated in 
liquid culture medium [80,99,101]. Extracellular polysaccharides have 
also been isolated from the culture medium of growing mycelium [70]. 
Polysaccharides from G. lucidum with antitumor properties such as 
the branched heteroglucan and arabinoxyloglucan (GL-1) have been 
observed initially in subcutaneously transplanted sarcoma-180 ascites 
growing in mice [71]. This heteroglucan inhibited significantly the 
growth of sarcoma-180 solid-type tumor (Inhibition ratio, 95.6–98.5%) 
after intra-peritoneal injection (20 mg/kg) for 10 days in imprinting 
control regions of mice [71]. The G. lucidum polysaccharides (GLP) 
of G. lucidum also exhibited antitumor activity against solid tumor 
induced by Ehrlichs ascites carcinoma cells. These polysaccharides 
of G. lucidum showed 81.2% and 79.5% inhibition of tumor mass 
and tumor volume, respectively, when administered before tumor 
inoculation at the dose of 100 mg/g. However, these polysaccharides 
at the same dose showed 80.8% and 77.6% reduction in tumor volume 
and tumor mass, respectively, when administered 24 h after tumor 
cell implantation [102]. The G. lucidum polysaccharide peptide (GLPP) 
of G. lucidum when added to the cultured medium did not showed 
inhibition of human lung carcinoma (PG cell line) proliferation in 
vitro; however, GLPP-treated serum significantly inhibited PG cell line 
proliferation in vitro and reduced the xenograft (PG cell line) in BALB/c 
nude mice in vivo [103]. The antitumor activity of polysaccharides 
of Ganoderma fruiting body and mycelium with (1→3)-β-D-glucan 
bonds has also been reported by Sone et al., 1985 [70]. The antitumor 
property of Ganoderma polysaccharides is mostly related to their 
immunomodulatory activity. These polysaccharides cannot penetrate 
the host cells because of large molecular weight however they bind to 
immune cell receptors. It is widely known that there are fungal pattern-
recognition molecules for the innate immune system. The mechanism 
through innate immune system recognizes and responds to the 
polysaccharides of the fungal cell wall is a very complex and multifactorial 
process [104]. The activity of polysaccharides from G. lucidum has been 
found to be mediated through the compliment receptor Type 3 (CR3 
receptor), which binds β-glucan polysaccharides [105]. Ganoderma 
polysaccharides exert their bioactivity through the activation of 
the immune response of the host, thereby enhancing the defense 
system of host [23]. The water-soluble antitumor polysaccharide-
enriched fractions from Ganoderma are believed to be related to the 
stimulation of interleukin (IL)-1β, tumor necrosis factor (TNF)-α, IL-6 
from human monocyte-macrophages, and interferon (INF)-γ from T 
lymphocytes [25]. The polysaccharides from G. lucidum (Homo-glucan) 
are known to exert its antitumor activity in sarcoma-180 solid tumor 
by inducing a cascade of immunomodulatory cytokines. It also resulted 
in the significant increase in the gene expression levels of IL-1α, IL-1β, 
TNF-α, IL12 p35, and IL-12 p40 in the splenocytes. Polysaccharides 
from G. lucidum are also known to promote a remarkable increase in 
the gene expression levels of IL-β, TMF-α, and granulocyte-macrophage 
colony-stimulating factor in the macrophages [106]. Polysaccharides 
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from G. lucidum not only have(1→3)-β-D-glucan bonds but also has 
(1→6)-β-D branches. The structural features such as (1→3)-β-linkages 
in the main chain of the glucan and additional (1→6)-β-branch points 
are considered important factors to be responsible for the antitumor 
activity. The similar results were studied for the heteroglucan from G. 
tsugae, which were composed of (1→3)-β-D-glucans and (1→4)-α-D-
glucans having antitumor property against sarcoma-180 solid 
tumor [80]. Pan et al., 2013 [107], have isolated polysaccharide (GLP) 
from G. lucidum which was optimized by response surface method 
(RSM). The results showed that the GLP reduced the levels of serum 
IL-6 and TNF-α level significantly and caused increase in the levels 
of serum IL-2, IL-4, and IL-10 in GLP-treated rats as compared to 
gastric cancer model rats. Various other heteropolysaccharides from 
Ganoderma have been studied very recently both in vitro and in vivo 
conditions, with inhibitory activity in tumor cell lines, inhibition of 
tumors transplanted in mice, and induction of apoptosis [99,108,109]. 
Polysaccharides from G. lucidum have been found to suppress growth of 
lung cancer cells and prostate cancer cells [35,110]. In a recent study by 
Kumar et al., 2017 [111], the authors reported that gold nanoparticles 
(Au-NPs) which were synthesized from G. lucidum and conjugated with 
doxorubicin drug showed significant anticancer drug accumulation 
and cytotoxic activity against MCF-7-doxbreast cancer cell line. Au-
NPs reduced 97% growth of MCF-7-doxbreast cancer cell line at higher 
concentration (400 μ M/ml). The mRNA expression of ABCB1 gene 
and CDNA synthesized from human breast cancer cell line (MCF-7) 
showed reduced expression. It is, thus, necessary to conclude that the 
pharmacological activity of G. lucidum exhibits the anticancer activity 
of newly synthesized Au-NPs conjugated with drug doxorubicin [111].
ANTIOXIDANT ACTIVITIES
Antioxidant activities include free-radical scavenging properties, 
chelating effects on ferrous ions, and reducing power [112,113]. The 
radical scavenging activity seems to be related with an increase in the 
activities of antioxidant enzymes, catalase (CAT) which causes the 
detoxification of hydrogen peroxide and converts lipid hydroperoxides 
(LOOH) into less or non-toxic substances, superoxide dismutase (SOD) 
which help in the catalysis of superoxide anion to hydrogen peroxide 
and glutathione peroxidase (GSH-Px) which maintains the levels 
of reduced GSH [114]. Polysaccharides from Ganoderma have been 
found to exhibit strong antioxidant activity [115-117]. Ganoderma 
polysaccharides have shown antioxidant activity both in vivo and in vitro 
activities, which suggested that they act as novel antioxidant agents in 
the promotion of human health and therefore improve oxidative stress 
associated pathologies. Homo-glucans and hetero-glucans of G. lucidum 
have shown very much promising radical scavenging activities, as 
evaluated by various antioxidant methods, such as 2,2-diphenyl-1-
picrylhydrazyl (DPPH) scavenging assay, chelating ability, reducing 
power, hydroxyl radical scavenging activity, superoxide, and hydrogen 
peroxide scavenging activity [109,112-118]. The low molecular weight 
polysaccharide isolated from G. lucidum such as β-1, 3-glucan was 
able to increase the viability from 40% to 80%, of a mouse leukemic 
monocyte macrophage cell line (RAW 264.7) with H2O2-induced 
oxidative stress. This low molecular weight, β-1, 3-glucan, is known to 
reduce the reactive oxygen species formation and it also suppressed 
the activities of acidic and neutral sphingomyelinases (SMases) [119]. 
Kan et al., 2015 [120], reported antioxidant activity of polysaccharides 
extracted from G. lucidum using response surface methodology. The 
homo-polysaccharide composed of mannose isolated from Ganoderma 
displayed very high radical scavenging activity by increasing the 
activity of antioxidant enzymes, SOD, CAT, GSH-Px, and decreasing 
malondialdehyde (MDA) levels in rats with cervical and ovarian 
cancer [114]. The antioxidant activity of G. lucidum polysaccharide 
(GLPS) against exercise induced oxidative stress significantly increased 
the activity of antioxidant enzymes; SOD, CAT, and GSH-Px and decreased 
the levels of MDA [121]. The hetero-glucan also isolated from G. lucidum 
showed significant antioxidant activity against mitochondria oxidative 
injury induced by γ-irradiation, which caused an enormous decrease 
in MDA levels, LOOH and formation of carbonyl protein, while the 
formation of thiol protein increased. This hetero-glucan also resulted 
in the increased activities of antioxidant enzymes, SOD, CAT, and GSH-
Px [122]. The main linkages which were present in the homo-glucans 
were β-(1-3), (1-4), and (1-6) glycosidic bonds, as also in the hetero-
glucans were, composition of different sugars is, mannose, galactose, 
glucose, rhamnose, xylose, arabinose, and fucose in varying proportions. 
The polysaccharides such as homo-glucans and hetero-glucans were 
isolated by Liu et al. [112] and reported higher antioxidant activity 
of the homo-glucan due to its comparatively low molecular weight. 
However, hetero-glucans isolated with different molecular weights 
showed highest anti-oxidant activities for the polysaccharide with 
the highest molecular weight [109]. Pan et al., 2013 [107], isolated 
polysaccharide (GLP) from G. lucidum which was optimized by RSM. The 
results showed that the GLP reduced the levels of serum IL-6 and TNF-α 
levels significantly and caused increase in the levels of serum IL-2, IL-4, 
and IL-10 in GLP-treated rats as compared to gastric cancer model rats. 
Further, the administration of G. lucidum polysaccharides to GLP-treated 
group of rats increased the levels of CAT, SOD, and GSH-Px in serum and 
gastric tissue against the control values in dose dependent manner. This 
experiment showed that the G. lucidum polysaccharide can enhance 
immunity and antioxidant activities in gastric cancer rats.
Chen and Wu 2014 [123] designed a novel and very efficient technique 
for extracting the crude antioxidant polysaccharides. In this technique, 
dried fruiting bodies of G. lucidum were finely pulverized into ultrafine 
powder, subsequently to extract the crude antioxidant polysaccharides 
by ultrasonic circulating extraction. Various extraction factors were 
investigated by single factor analysis with the help of DPPH radical 
scavenging activity as an index. After this, multiple regression equations 
were worked out through which optimal processing conditions can be 
predicted and therefore predicted model was verified experimentally. 
The highest polysaccharide concentration, that is, 47.87 mg/ml, 
along with highest DPPH scavenging rate 53.63% was achieved at 
671 W ultrasonic powder, 48°C extraction temperature, 5.5/1 of 
intermit-running ratio (s/s), 1:12.5 of solid-liquid ratio (w/v), and 
45 min extraction time. The results showed that this novel technique 
proved to be very efficient for high extract yield of crude antioxidant 
polysaccharide from G. lucidum.
IMMUNOMODULATION
The polysaccharides of Ganoderma are known for significant 
immunomodulating properties, which enhanced the function of 
mononuclear phagocyte system, antigen presenting cells, humoral 
immunity, and cellular immunity [28,48]. The isolated and identified 
polysaccharides from Ganoderma have been demonstrated to modulate 
and improve immune function both in human studies and mouse 
models [124]. During the administration of polysaccharide extracts 
of G. lucidum, there was increase in the secretion of cytokines from 
immune cells which lead to increased cellular activity and survival of 
immune cells related to adaptive immunity (Lymphocytes) and innate 
immunity (Macrophages) [125,126]. Chang et al., 2004 [3], and Pan 
et al., 2013 [107], have also reported that these polysaccharides have 
been found to improve the activity of cytotoxic T-lymphocytes and 
natural killer cells. The polysaccharide peptide (GLPP) from G. lucidum 
when administered intraperitoneally significantly increased the survival 
rate of macrophages which were injured by tert-butylhydroperoxide 
under in vitro and in vivo conditions [127]. Zhu et al., 2007 [128], 
reported that the phagocytosis and cytotoxicity of macrophages were 
increased significantly in cyclophosphamide (Cy)-treated mice after 
the treatment with polysaccharides from G. lucidum at low dose (2.5 
mg/kg) for 12 days. The Ganoderma polysaccharides have also been 
reported to enhance the expression of major histocompatibility complex 
in a melanoma cell line, which improves antigen presentation thereby 
promoting cancer and viral immunity [129]. Sun et al., 2011 [129], have 
reported the promoting effects of the polysaccharides from G. lucidum on 
B16F10 cells which help in the activation of lymphocytes. The treatment 
of T lymphocyte or macrophage culture medium with G. lucidum 
polysaccharides increased the TNF-α and IFN-γ release in dose-
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dependent and time-dependent instances [130]. Cao and Lin 2002 [131] 
have reported that the polysaccharides from G. lucidum promoted the 
maturation of cultured murine bone marrow derived dendritic cells. 
The effects of Ganoderma polysaccharides on the immune functions of 
the patients with the advanced cancer stages were also investigated and 
the results showed that the Ganoderma polysaccharides significantly 
lead to the increase in the concentration of IL-2, IL-6, IFF-γ, the absolute 
number of CD56+ cells, and the NK activity also showed increase from 
the baselines after 12-week treatment. However, it was observed that 
the levels of IL-1 and TNF-α decreased significantly. When compared 
to pretreatment baselines after 12-week treatment with Ganoderma 
polysaccharides, it was reported that the phytohemagglutinin responses 
were enhanced in most patients. Thus, these results showed that the 
Ganoderma polysaccharides could significantly enhance the immune 
responses in patients with advanced cancer stages [124,132]. Huang 
and Ning [133] isolated polysaccharide from G. lucidum by RSM to 
optimize the ultrasonic/microwave-assisted extraction conditions. 
The immunological studies showed that G. lucidum polysaccharides 
extracted by ultrasonic/microwave (UMP) could improve the weight 
of immune organ of immunocompromised mice, improve hemolysis 
antibody level, restore delayed-type hypersensitivity reaction to DFNB, 
and natural killer cell activity at high doses. However, UMP did not 
seem to be had any noticeable effect on phagocytosis of monocytes 
at the tested dose ranges. It is, thus, clear that the polysaccharides of 
Ganoderma have robust immunomodulatory properties both in vivo 
and in vitro conditions. The polysaccharides from Ganoderma enhanced 
the immune responses of the human body during the experiments on 
advanced cancer stage patients to exhibit the antitumor effects.
ANTIMICROBIAL PROPERTIES
Fungi are known for the production of very important antibiotics, such 
as penicillin. However, the search for the presence of antibiotics in 
mushrooms is less documented [134]. Mushrooms have been thought 
to possess weak antifungal activity [23,33] and thus have not been 
scrutinized for their antifungal activity. Very recently mushrooms have 
become of interest due to the occurrence of secondary metabolites 
which possess wide range of antimicrobial activities. Ganoderma 
mushroom has been studied for their therapeutic properties as 
antiviral and antitumor agents but have been far less studied for their 
antimicrobial property [135-137]. Majority of the antibacterial studies 
on Ganoderma species have been carried out on the fruiting body and 
there are relatively few studies which have been performed on extracts 
from the liquid cultivated mycelium. Wasser 2011 [85] has reported 
that eastern and western medicine system has adopted various 
regulatory systems for mushroom and herbal preparations. As per 
the studies of Sullivan et al., 2006 [138], western medicine has made 
much little use of medicinal mushroom products partly because of 
their complex structure and lack of acceptable pharmacological purity. 
Researchers working on the active compounds from Ganoderma have 
worked on extracts from the mycelium and fruiting body, and there 
only few reports on antimicrobial activity of isolated polysaccharides. 
It is, therefore, quite obvious, that there are a number of biologically 
active compounds to be found in the fruiting body and mycelium, 
but the antimicrobial activity evaluation of chemically characterized 
polysaccharides is very much limited. It has also been found that the 
(1→3)-β-D- glucan with (1→6)-β-D branches could act as antimicrobial 
agents. Bhattacharyya et al., 2006 [136], have reported that the 
polysaccharides from the basidiocarp and mycelia of G. applanatum 
were found to possess antimicrobial activity against Bacillus brevis, 
Bacillus subtilis, Acrobacter aerogenes, Arthrobacter citreus, Acetobacter 
aerogenes, Escherichia coli, Corynebacterium insidiosum, Proteus 
vulgaris, Clostridium pasteurianum, Micrococcus roseus, Mycobacterium 
phlei, Staphylococcus aureus, and Sarcina lute. In another study by 
Bai et al., 2008 [139], polysaccharides from G. lucidum were tested 
for antimicrobial activity against three plant pathogens, namely 
(Penicillium digitatum, Erwinia carotovora, and Botrytis cinerea), and 
five food harmful microorganisms (B. subtilis, Bacillus cereus, E. coli, 
Rhizopus nigricans, and Aspergillus niger). After the investigation, 
the results showed that the polysaccharides had inhibitory effect on 
E. carotovora, weak inhibitory on P. digitatum and nearly non-inhibitory 
effect on B. cinerea for the plant pathogens. With respect to the harmful 
food microorganisms, the polysaccharides showed strong inhibitory 
effect on B. subtilis and B. cereus, weak inhibitory effect on E. coli and 
A. niger and nearly non-inhibitory effect on R. nigricans [139].
The polysaccharides from Ganoderma have been much investigated 
against several pathogenic bacteria [32,140]. So far various authors 
have reported antimicrobial activity of different extracts of G. lucidum 
but not of isolated polysaccharides [141,142]. The extracts from 
G. lucidum have shown strong antifungal, antibacterial, demelanizing 
properties even better than the standard streptomycin (STZ), and 
ampicillin in few cases. Therefore, the polysaccharides of Ganoderma 
in general and G. lucidum in particular should be investigated, since 
they have strong participation in antimicrobial properties. Paul et al., 
2015 [143], synthesized silver nanoparticles (AgNPs) from G. lucidum 
and impregnated the cotton fabrics with these synthesized AgNPs to 
check the antimicrobial activity. The antibacterial activity of silver 
impregnated cotton was investigated and results showed strong 
and robust activity against three pathogens, Streptococcus aureus, 
Pseudomonas species, and Proteus species. Hence, it is revealed that 
dressing material incorporated with AgNPs can be used as sterile 
fabric that could be used commercially against infections and wounds. 
Very recently the antimicrobial activity of G. lucidum against Candida 
Biofilms has been evaluated [144]. In this study, the mycelial aqueous 
extracts of G. lucidum demonstrated higher anti-Candida activity and 
ascorbic acid (potent antioxidant) content among all the extracts 
and fractions. This study further reveals the preventive effect against 
Candida albicans and Candida glabrata biofilms due to the activity of 
G. lucidum extracts which will prove very beneficial for humanity as 
Candida is potent pathogen.
NEUROPROTECTIVE EFFECT
The constituents of G. lucidum include triterpenoids, polysaccharides, 
unsaturated fatty acids, and ergosterol. Among these, polysaccharides 
are, however, the major pharmacologically active compound. The 
effects of polysaccharide extracts of G. lucidum have been related 
to promote suppression of cancer cell migration, innate immune 
responses, and modulations of cell proliferations [57,145-147]. In last 
few years, studies have shown that the G. lucidum show neuroprotective 
activity and significantly weakened amyloid beta (Aβ) peptide-induced 
neurotoxicity [148]. Zhou et al., 2012 [149], have reported that the 
pre-administration of spores of G. lucidum to rats may also protect the 
hippocampus from the oxidative damages. All of these results showed 
positive implications for G. lucidum in the treatment of Alzheimer’s 
disease (AD). However, there are very less reports in the biochemical 
mechanism to which polysaccharides of G. lucidum might target AD. The 
cause of AD is very complex mechanisms and has not been fully resolved 
yet. Two important distinguishing characteristics which characterize 
this neurodegenerative disease are the aggregation of Aβ which leads 
to senile plaques and the progressive cognitive impairments [150]. 
The deposition of Aβ results into the activation of microglia, the 
resident immune cells and therefore causes neuroinflammation in 
the central nervous system (CNS) [151]. The activation of microglia 
results in the release of pro-inflammatory cytokines and neurotoxic 
mediators with altered cell behaviors, which may be characterized 
by the microglial morphology, migration, and phagocytosis [152]. 
The positive feedback from microglial phagocytosis is the removal 
of dead neurons and neuronal debris that helps in the reduction 
of inflammatory stress. Nevertheless, extended activation by TLR 
agonists, such as lipopolysaccharides (LPS), Aβ, and lipoteichoic acid 
might result into aberrant phagocytosis process [153,154]. Under these 
conditions, microglia target on live neurons, neuronal progenitor cells, 
and glioma cells, all of which leads to neuronal loss in the CNS [153]. 
Other than the pro-inflammatory mediators, chemokines such as 
MCP-1 also accumulate as a result of neuroinflammation. The over-
expression of MCP-1 has been observed in many neurodegenerative 
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diseases [155-157]. In the AD brain, the function of MCP-1 is related to 
cell movement and to initiate the accumulation of monocytes at the site 
of Aβ deposition [158-160]. Upregulation of MCP-1 expression might 
contribute to the chronic inflammation [161].
Very recently, Cai et al., 2017 [162], provided a view into the regulatory 
roles of polysaccharides from G. lucidum in LPS and Aβ-induced 
microglial behavior and pro-inflammatory responses. These authors 
revealed that the polysaccharides from G. lucidum reduced the pro-
inflammatory cytokines and MCP-1 expressions with a tendency to 
promote anti-inflammatory cytokine levels. They also demonstrated 
that the polysaccharide from G. lucidum modulation of microglial 
behavioral changes in vitro was associated to MCP-1 expressions. 
Finally, it was also confirmed that the polysaccharides from G. lucidum 
modulated microglial behavioral changes in vivo. These observations 
indirectly reveal that polysaccharides from G. lucidum show a 
neuroprotective function in the treatment of AD. In association with 
the neurogenesis effect Huang et al., 2017 [163], polysaccharides from 
G. lucidum represents a dual functional cocktail-like natural product, 
which bears a great and robust potential in the early prevention and 
treatment of AD.
HYPOGLYCEMIC ACTIVITIES
The hypoglycemic property of Ganoderma polysaccharides has 
been widely studied and the studies on animals have suggested 
that polysaccharides from Ganoderma might help in the prevention 
of diabetes and slow down the progression of diabetes once it has 
developed. It has been found that polysaccharides from G. lucidum 
could significantly increase the levels of insulin and decrease blood 
glucose in STZ-induced diabetic mice [164,165]. The hypoglycemic 
activities of G. lucidum polysaccharides have been determined in 
patients having Type II diabetes mellitus and the results demonstrated 
that these polysaccharides of G. lucidum were efficient and safe in 
lowering concentration of glucose in blood [166]. Polysaccharides 
from G. lucidum could also significantly reverse alloxan-induced 
islets viability loss by inhibiting the free radical production, reducing 
serum glucose levels, and increasing serum insulin in alloxan-induced 
diabetic mice dose-dependently [167]. This study suggested that 
polysaccharides of G. lucidum had a protective effect on alloxan-induced 
pancreatic islets damage under in vivo and in vitro conditions [167]. 
Further, polysaccharides from G. lucidum have also been investigated 
to possess potential beneficial effects on diabetic complications. The 
polysaccharides from G. lucidum exhibited renal protective effect in 
mice with diabetic nephropathy through the amelioration of metabolic 
disorders, renal dysfunction associated with renal lesions, and oxidative 
stress [164]. He et al., 2006 [164], reported that the treatment of 
polysaccharides of G. lucidum reduced the levels of blood urea nitrogen, 
serum creatinine, serum glucose, and urine albumin excretion in a 
dose-dependent manner compared with diabetic model mice. He et al., 
2006 [164], also reported that the polysaccharides from G. lucidum 
could be used in the treatment of myocardial fibrosis of diabetes. The 
polysaccharides from G. lucidum weakened the myocardial collagen 
cross-linking in diabetic rats which was related to the decreased level 
of advanced glycation endproducts and increased the activities of 
the antioxidant enzymes. Meng et al., 2011 [165], reported that the 
polysaccharides from G. lucidum have the capacity to weaken the renal 
morphometric changes and oxidative stress of diabetic mice. Pan et al., 
2012 [168], isolated a neutral polysaccharide (FYGL-1) which was 
fractionated from the hypoglycemic extract FYGL by DEAE-52 cellulose 
column chromatography of G. lucidum. The molecular weight of FYGL-
1 was found to be 78 KDa. Furthermore, the monosaccharide analysis 
showed that FYGL-1 was a heteropolysaccharide consisting of galactose, 
rhamnose, and glucose residues in the molar ratio of 1.00:1.15:3.22. 
The backbone structure of FYGL-1 consisted mainly of 1,2-linked-β-L-
Rhap, 1,3,6-linked-α-D-Galp, 1,2,6-linked-α-D-Glcp, and 1-linked-α-D-
Glcp, based on the analysis of methylation, periodate oxidation, smith 
degradation, and 1D and 2D NMR. The previous studies on G. lucidum 
had shown beneficial effects on Type 2 diabetes mellitus in murine 
molds; however, the effects of this mushroom on the gut microbiota, 
inflammation, and obesity had not been investigated. Recent study 
by Chang et al., 2015 [63], on mice investigated that water extract of 
G. lucidum mycelium (WEGL) prevents dietary-induced obesity and 
alleviates inflammation by modulating the gut microbiota composition 
and maintaining intestinal barrier integrity. Chang et al., 2015 [63], 
concluded that WEGL showed significant changes in the gut microbiota 
composition and the anti-obesity activity of WEGL is transferrable 
through fecal transplantation support the concept that obesity is 
associated with an altered gut microbiota composition (e.g., reduction 
of Escherichia fergusonii).
HEPATOPROTECTIVE ACTIVITY
Hepatoprotective activity of G. lucidum polysaccharides against Bacillus 
of Calmette Guerin (BCG)-induced immune injury of liver was studied 
in mice by determining the activity of alanine aminotransferase (ALT) 
in serum and hepatocytes cultured supernatant, NO production in the 
cultured supernatant, histological examination, and liver weight changes 
[169]. These observations showed that G. lucidum polysaccharides 
significantly mitigated hepatic tumefaction, decreased ALT enzyme 
release and NO production in the serum/supernatant, and improved 
the pathological changes of acute and chronic inflammation induced 
by BCG-stimuli in mice. In addition, it was further reported that the 
polysaccharides of G. lucidum inhibited iNOS protein expression in BCG-
immune hepatic damage model. This finding by Zhang et al., 2002 [169], 
also revealed that the NO participation in immune liver injury induced 
by Mycobacterium bovis BCG infection and the mechanism of protective 
roles by G. lucidum polysaccharides for BCG-induced immune liver injury 
might be because of the influencing NO production in mice. Gao et al., 
2003 [170], and Pham et al., 2016 [171], also observed hepatoprotective 
activity of G. lucidum with respect to cyclophosphamide induced liver 
injury in mice. Zhu et al., 2016 [172], reported the beneficial effects of 
polysaccharide isolated from G. atrum (PSG-1) on the liver function in 
diabetic rats (Type 2). The results revealed that the polysaccharide (PSG-
1) reduced the activities of serum ALT and aspartate aminotransferase, 
while increasing the hepatic glycogen levels. Polysaccharide PSG-1 
also exhibited very strong antioxidant activities, together with the 
upregulation of mRNA expression of peroxisome proliferator-activated 
receptor-γ, glucose transporter-4 (GLUT4), phosphoinositide 3-kinase 
(PI3K), and phosphorylated-Akt (p-Akt) in the liver of diabetic rats. 
Furthermore, after treating diabetic rats with PSG-1 for 4 weeks, the 
concentrations of short-chain fatty acids (SCFA) were significantly 
higher in the liver, serum, and feces. These results recommended that 
the improvement of PSG-1 on liver function in Type 2 diabetic rats 
might be due to its antioxidant property, SCFA excretion in the colon 
from PSG-1, and regulation of hepatic glucose uptake by inducing 
GLUT4 translocation through PI3K/Akt signaling pathways. Very 
recently, Yu et al., 2017 [173], studied that G. lucidum polysaccharides 
have a therapeutic effect on hepatocellular carcinoma (HCC) cells 
exposed to radiation. The authors concluded that the GLP enhances the 
radiosensitivity of HCC cell lines through the regulation of Akt signaling 
pathways, implying a potential therapeutic effect of GLP as a radiation 
sensitizer in HCC treatment.
In some studies, it has been found that the bioactivity of Ganoderma 
polysaccharides may be due to the alkali soluble polysaccharides and/
or water insoluble polysaccharides and water-soluble polysaccharides. 
The water insoluble, but alkali-soluble glucan G-A has been isolated 
from Ganoderma japonicum [72]. A water soluble and low branched 
polysaccharide (SGL-III) has been isolated from the spores of 
G. lucidum [174]. A water-soluble polysaccharide, heteropolysaccharide 
LZC-1 has been isolated from G. lucidum [76]. The water-insoluble 
glucans, namely, GL4-1 and GL4-2 have been isolated from the fruiting 
bodies of G. lucidum [175]. Neutral polysaccharide, soluble in water 
was isolated by Huang et al., 2011 [176], from G. lucidum fruiting body. 
Neutral, water soluble, and hetero-polysaccharide (GLPS3) have been 
isolated from germinating spores of G. lucidum [177]. A novel water 
soluble and neutral β-D-glucan (GLSA50-1B) have been isolated from 
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the spores of G. lucidum [178]. A water-soluble b-glucan (DESSK5) 
was reported in the basidiocarp of G. resinaceum [179]. Novel hetero-
polysaccharides (GL-1 to GL-5) have also been isolated from the fruiting 
bodies of G. lucidum [137]. However, these polysaccharides need further 
evaluation for their potential bioactivities, as their chemical properties 
are very much promising.
CONCLUSION
The beneficial health properties of Ganoderma species have been 
attributed to the variety of bioactive compounds. Ganoderma genus 
in general and G. lucidum in particular can be considered as a natures 
pharmaceutical store due to the presence of various bioactive 
compounds isolated till date and demonstrated to have numerous 
therapeutic activities. G. lucidum has been extensively used for centuries 
for numerous pharmacological benefits, including immune-modulating, 
anticancer, anti-oxidant, anti-aging, antimicrobial, anti-inflammatory 
effects, and only very recently these claims have been accepted due to 
the scientific information that has become available. Certainly and from 
the enormous work carried out, Ganoderma species offers concrete 
promises for the development of therapeutic drugs, nutraceuticals, 
and novel functional foods. Extensive literature has been reported 
on bioactive compounds of G. lucidum, but further clinical studies are 
still needed to demonstrate their therapeutic efficacy. Furthermore, 
there is need of more studies regarding the safety and application of 
these bioactive metabolites for providing more convincing evidence 
to shift to application stage from just clinical trials. The future studies 
should also focus more on the mechanisms of action of G. lucidum and 
related species of Ganoderma, because most of them are not very well 
known and thus need to be understood properly. Moreover, various 
polysaccharides isolated from Ganoderma species have unknown 
sugar composition and unreported bioactivity, thus more work is 
needed to identify these polysaccharides and work on their bioactivity. 
Therefore, G. lucidum can represent practical and promising approach 
for cancer prevention and cancer treatment and other ailments based 
on current data available from in vivo and in vitro studies. However, 
further experimental, epidemiological and clinical studies are needed 
to identify the molecular targets, to resolve the relationships between 
different ailments and uptake of Ganoderma and to explore the dosing, 
efficacy and safety along with chemotherapy and radiotherapy.
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